Subsidy Information and Financing Scheme MAFTofacitinib Tablet 5 mg Additional clinical criteria applies 1) Treatment of adults with rheumatoid arthritis. 2) Treatme... See all × MAFTofacitinib Tablet 5 mg Additional clinical criteria applies 1) Treatment of adults with rheumatoid arthritis. 2) Treatment of adults with moderately to severely active ulcerative colitis who have failed conventional therapy and/or anti-TNFα biologics.
Drug Guidance for Subsidy 01/07/2022 Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis The Ministry of Health’s Drug Advisory Committee has recommended: Baricitinib 2 mg and 4 mg t... See all × 01/07/2022 Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis The Ministry of Health’s Drug Advisory Committee has recommended: Baricitinib 2 mg and 4 mg tablets for treating adults with moderately to severely active rheumatoid arthritis; Tofacitinib 5 mg tablet for treating adults with moderately to severely active rheumatoid arthritis; and Rituximab biosimilar (Truxima) 500 mg concentrate for infusion for treating adults with severely active rheumatoid arthritis in line with their registered indications. Subsidy status RBaricitinib 2 mg and 4 mg tablets and tofacitinib 5 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication. RBaricitinib and tofacitinib should be used in line with the clinical criteria in the MAF checklist for initial and continuing prescriptions for patients with rheumatoid arthritis. RRituximab biosimilar (Truxima) 500 mg concentrate for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication. NRSDL subsidy and MAF assistance does not apply to any formulations or strengths of tocilizumab, rituximab reference biologic (MabThera) or other rituximab biosimilars (such as Rixathon). 01/07/2022 Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease The Ministry of Health’s Drug Advisory Committee has recommended: Tofacitinib 5 mg tablet for... See all × 01/07/2022 Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease The Ministry of Health’s Drug Advisory Committee has recommended: Tofacitinib 5 mg tablet for treating adults with moderately to severely active ulcerative colitis (UC) who have failed conventional therapy and/or anti-TNFα biologics; and Vedolizumab 300 mg/vial powder for concentrate for solution for infusion for treating adults with moderately to severely active Crohn’s disease (CD) who have failed both conventional therapy and anti-TNFα biologics. Subsidy status RTofacitinib 5 mg tablets and vedolizumab 300 mg/vial powder for concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications. RTofacitinib and vedolizumab should be used in line with the clinical criteria for initial and continuing prescriptions for patients with UC and CD in the respective MAF checklists. RListing on MAF will be implemented on 1 July 2022. NRMAF assistance does not apply to any formulations or strengths of ustekinumab for treating CD and UC.
Post Marketing Information DHCPL 17/11/2022 Risk of major adverse cardiovascular events, malignancy, thrombosis and death associated with use of Janus Kinase (JAK) inhibitors DHCPL 29/03/2021 Risk of major adverse cardiovascular events and malignancies (excluding non-melanoma skin cancer) with use of Xeljanz (tofacitinib) relative to tumour necrosis factor inhibitors
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 5 mg Alexandra Hospital Changi General Hospital KK Women's and Children's Hospital Khoo Teck Puat Hospital National Skin Centre National University Hospital Sengkang General Hospital Singapore General Hospital Tan Tock Seng Hospital